Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., Cheng, F., Chen, J., Bařinka, C., Pinilla-Ibarz, J., Lee, N. H., Kozikowski, A., Villagra, A. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports. 2019, 9(APR 16 2019), 6136. ISSN 2045-2322. E-ISSN 2045-2322. Available: doi: 10.1038/s41598-019-42237-3.